Login to Your Account



A Blockbuster Opportunity

Kalydeco Combo Surprises with Lung Function Benefit

By Catherine Shaffer
Staff Writer

Tuesday, May 8, 2012
Cystic fibrosis patients received welcome good news Monday, as Vertex Pharmaceuticals Inc. reported that its ongoing Phase II trial of VX-809 and Kalydeco (ivacaftor) showed significant lung function improvements in an interim analysis of patients homozygous for the F508del mutation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription